Coloplast A/S

Equities

COLO B

DK0060448595

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Copenhagen Other stock markets 08:29:32 15/05/2024 pm IST			5-day change	1st Jan Change
837.4 ^DKK	+0.29%		-0.59%	+8.47%

15/05	COLOPLAST : Multiple silver linings in spite of a soft Q2 24
07/05	European shares hit one-month high as earnings take centre stage	RE

Coloplast A/S : Company mission and sustainability strategy

March 22, 2022 at 09:22 pm IST

Coloplast's ESG event

22 March 2022

Company mission and sustainability strategy

Wanyong,

China

Kristian Villumsen

President & CEO

Making life easier

Making life easier for people with intimate healthcare needs

Stina,

Sweden

Katryna,	Wanyong,	Emma,
UK	China	Japan

Tabitha,	Bob,
UK	US
	Kristian,
	Denmark

Victor,	Brian,	Anna,
Denmark	US	Sweden

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Coloplast A/S published this content on 22 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2022 15:51:08 UTC.

Latest news about Coloplast A/S

COLOPLAST : Multiple silver linings in spite of a soft Q2 24	15/05
European shares hit one-month high as earnings take centre stage	07/05	RE
U.S. Futures Flat, European Stocks Rise	07/05	DJ
European shares hit one-month high on upbeat earnings, rate-cut optimism	07/05	RE
Transcript : Coloplast A/S, H1 2024 Earnings Call, May 07, 2024	07/05
Coloplast Posts Higher Fiscal H1 Net Profit, Revenue	07/05	MT
Coloplast Strengthens Ostomy Care Portfolio with Three Significant Product Launches	07/05	CI
Coloplast A/S Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	07/05	CI
Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24	07/05	CI
Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024	07/05	CI
Certain B Shares of Coloplast A/S are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	27/02	CI
COLOPLAST : Q1 24: Many more positives beyond the margin beat	14/02
Nordic Shares Moved Upward Friday; Kongsberg Gruppen Topped Leaders	09/02	DJ
Global markets live: Tesco, Boeing, Roche, Exxon Mobil, PepsiCo...	09/02
Transcript : Coloplast A/S, Q1 2024 Earnings Call, Feb 09, 2024	09/02
European shares flat as higher yields counter earnings bump	09/02	RE
European shares inch up on earnings bump, higher yields weigh	09/02	RE
Coloplast Posts Growth in Fiscal Q1 Net Profit, Revenue	09/02	MT
Coloplast Launches Peristeen Light for People with Bowel Disorders	09/02	CI
Coloplast A/S Reports Earnings Results for the First Quarter Ended December 31, 2023	09/02	CI
Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24	09/02	CI
Coloplast Rolls Out New Silicone Foam for Wound Care in US	31/01	MT
Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US	31/01	CI
Nordic Stocks Decreased Wednesday; Kone B Posted Biggest Loss	17/01	DJ
COLOPLAST : EPS cut (2023: -12.9%, 2024: -14.7%)	04/01

Chart Coloplast A/S

Duration

Period

More charts

Company Profile

Coloplast A/S specializes in the design, manufacturing, and marketing of disposable medical products. Net sales break down by family of products as follows: - hygiene products (43.4%): urine bags, plugs, urinary testing systems and sets, etc.; - ostomy care products (36.8%): bags and equipment used following intestinal operations; - wound care and skincare products (11.9%): wound dressings, bandages, creams and gels; - voice and respiratory care products (7.9%): voice prostheses for speaking, adhesives, laryngectomy cannulas for breathing, hands-free speaking devices, etc. Net sales are distributed geographically as follows: Denmark (1.4%), the United States (21%), the United Kingdom (14%), France (10.8%) and other (52.8%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

20/08/2024 - Q3 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

COLOPLAST : Multiple silver linings in spite of a soft Q2 24

May 15, 2024 at 04:04 pm IST

More Strategies

Ratings for Coloplast A/S

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

835 DKK

Average target price

912.3 DKK

Spread / Average Target

+9.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Supplies

	1st Jan change	Capi.
COLOPLAST A/S	+8.47%	27.22B
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-29.43%	3.14B
WINNER MEDICAL CO., LTD.	-18.39%	2.47B
INTCO MEDICAL TECHNOLOGY CO., LTD.	+12.41%	2.35B
HARTALEGA HOLDINGS	+41.48%	2.14B
HARBIN FUERJIA TECHNOLOGY CO., LTD.	-1.23%	2.03B
TOP GLOVE CORPORATION BHD.	+40.00%	1.63B
NAKANISHI INC.	+5.74%	1.34B
KOSSAN RUBBER INDUSTRIES	+48.11%	1.29B
KANGJI MEDICAL HOLDINGS LIMITED	+9.30%	1.19B

Medical Supplies